Context Therapeutics Reports 29% Response Rate in PROC Phase 1 Trial
Interim RECIST v1.1 data from Context Therapeutics positions CTIM-76 as a clinical-stage candidate in a heavily pre-tre…
Interim RECIST v1.1 data from Context Therapeutics positions CTIM-76 as a clinical-stage candidate in a heavily pre-tre…
The network expansion signals growing operator demand for genomic optimization tools at the clinical fertility interfac…
The partnership signals growing operator interest in genomics-adjacent reproductive health services as precision nutrit…
The partnership signals growing operator demand for genetic optimization services within assisted reproduction — a cate…
An estimated 1 in 10 women of reproductive age live with endometriosis — a condition averaging a 7–10 year diagnostic d…
Pan-Canadian strategy roadmap identifies research and care gaps — opening a lane for evidence-backed nutraceutical and …
Pan-Canadian strategy roadmap identifies research, care, and policy gaps — opening space for evidence-backed nutraceuti…